RAPT
vs
S&P 500
RAPT
S&P 500
Over the past 12 months, RAPT has significantly outperformed S&P 500, delivering a return of +501% compared to the S&P 500's +11% growth.
Stocks Performance
RAPT vs S&P 500
Performance Gap
RAPT vs S&P 500
Performance By Year
RAPT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Rapt Therapeutics Inc
Glance View
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. FLX475 is in Phase I/II clinical trials. Its lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues.
